CGON - NASDAQ
CG Oncology, Inc. Common stock
$54.42
-0.85%CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
At a Glance
Live SnapshotCG Oncology, Inc. Common stock Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
CG Oncology, Inc. Common stock Income Statement
CGON • NASDAQ
| CG Oncology, Inc. Common stock Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
REVENUE | |||||
4M | 1.1M | 204K | 191K | 10.4M | |
GROSS PROFIT | |||||
(4.6M) | (0.0) | (0.0) | (15K) | (10K) | |
-607K | 1.1M | 204K | 176K | 10.3M | |
OPERATING INCOME | |||||
(190.2M) | (115.8M) | (55.7M) | (35.4M) | (23M) | |
(73.5M) | (33.7M) | (9.9M) | (6.4M) | (4.6M) | |
(116.6M) | (82.1M) | (45.8M) | (29M) | (18.3M) | |
-190.8M | -114.7M | -55.4M | -35.2M | -12.6M | |
PRE-TAX INCOME | |||||
(0.0) | (0.0) | (0.0) | (1K) | (451K) | |
0.0 | 26.6M | 6.9M | -1K | -451K | |
29.8M | 26.6M | 6.8M | -197K | -233K | |
-161M | -88M | -48.6M | -35.4M | -12.8M | |
NET INCOME | |||||
-161M | -88M | -48.6M | -35.4M | -12.8M |
SEC Filings
CGON - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 26, 2026 | May 20, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | April 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 26, 2025 | November 22, 2025 | 2025 |
Related Guides
Continue your CGON research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.